1-4 of 4
Ke Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Maura C. O'Leary, Xiaobin Lu, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiowjen Lee, Ke Liu, Bindu George, Wilson Bryan, Marc R. Theoret, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1142–1146.
https://doi.org/10.1158/1078-0432.CCR-18-2035
Published: 15 February 2019
View article titled, FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Open the PDF for FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufrin, Todd Palmby, Zedong Dong, Anne Marie Russell, Sarah Miksinski, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2289–2293.
https://doi.org/10.1158/1078-0432.CCR-12-1956
Published: 30 April 2013
View article titled, U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Open the PDF for U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma in another window
Journal Articles

Rare Cancer Trial Design: Lessons from FDA Approvals

Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5172–5178.
https://doi.org/10.1158/1078-0432.CCR-12-1135
Published: 30 September 2012
View article titled, Rare Cancer Trial Design: Lessons from FDA Approvals
Open the PDF for Rare Cancer Trial Design: Lessons from FDA Approvals in another window
Includes: Supplementary data
Journal Articles

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julie Bullock, Christoffer Tornoe, Sue Ching Lin, Terrance Ocheltree, Milinda Vialpando, Alice Kacuba, Robert Justice, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (20): 4921–4927.
https://doi.org/10.1158/1078-0432.CCR-10-1214
Published: 13 October 2010
View article titled, Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Open the PDF for Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary in another window